Qiagen (NYSE:QGEN) Receives $51.17 Average Target Price from Analysts

Shares of Qiagen (NYSE:QGEN) have been given a consensus rating of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $51.05.

Several analysts have recently issued reports on the stock. Stifel Nicolaus lowered their price objective on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. JPMorgan Chase & Co. upped their price target on shares of Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. Finally, Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Thursday.

Qiagen Stock Down 0.0 %

Shares of NYSE QGEN opened at $41.09 on Friday. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The firm has a fifty day moving average of $43.23 and a 200-day moving average of $43.57. The stock has a market capitalization of $9.38 billion, a PE ratio of 27.55, a P/E/G ratio of 3.18 and a beta of 0.42. The company has a quick ratio of 1.45, a current ratio of 1.84 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.59%. The company had revenue of $459.00 million during the quarter, compared to analysts’ expectations of $453.91 million. During the same period in the previous year, the company earned $0.53 EPS. The business’s quarterly revenue was down 5.4% compared to the same quarter last year. On average, analysts anticipate that Qiagen will post 2.13 EPS for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QGEN. Acadian Asset Management LLC boosted its position in Qiagen by 140.3% in the 3rd quarter. Acadian Asset Management LLC now owns 40,372 shares of the company’s stock valued at $1,634,000 after buying an additional 23,569 shares during the last quarter. Trexquant Investment LP purchased a new position in Qiagen in the 3rd quarter valued at about $1,069,000. Treasurer of the State of North Carolina boosted its position in Qiagen by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 103,065 shares of the company’s stock valued at $4,174,000 after buying an additional 523 shares during the last quarter. Toronto Dominion Bank purchased a new position in Qiagen in the 3rd quarter valued at about $41,000. Finally, Teza Capital Management LLC boosted its position in Qiagen by 21.9% in the 3rd quarter. Teza Capital Management LLC now owns 51,763 shares of the company’s stock valued at $2,096,000 after buying an additional 9,287 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.